Europe
Permira initiated the transaction after Cambrex flexed its own M&A muscle and acquired Avista and Halo.
Despite the data concerns, the U.S. Food and Drug Administration said it believes the gene therapy should remain on the market. Novartis said it stands behind the safety and efficacy of the therapy.
AstraZeneca and Merck plan on seeking regulatory approval for Lynparza as a treatment for a subset of prostate cancer patients based on the Phase III PROfound data.
Long Crendon, Buckinghamshire, UK, 6th August 2019 – Softbox, a leading global innovator and provider of temperature control packaging and thermal covers for the life science and logistics industries, has announced the appointment of Kevin Valentine as Softbox’s new global CEO, effective 1st September 2019.
Oxford Immunotec Global PLC, or the Company, a global, high-growth diagnostics company, announced second quarter 2019 financial results.
Agreement will address limitations in development of multiplex point-of-care Lateral Flow Assay diagnostic tests
Novo Nordisk intends to use the site to support manufacturing of its oral type 2 diabetes treatment that is under review for approval by the U.S. Food and Drug Administration.
Mallinckrodt said it remains committed to becoming an “innovation-driven specialty brands business.”
The vaccines are for Ebola Zaire, Ebola Sudan and the Marburg virus. Currently no licensed vaccines against these three viruses are available. All three diseases have a death rate of about 50%.
Basilea Pharmaceutica, based in Basel, Switzerland, announced positive topline data from its Phase III TARGET study of deftobiprole for acute bacterial skin and skin structure infections.
PRESS RELEASES